You have 9 free searches left this month | for more free features.

Condition

Proteus Syndrome (2)

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (1)

Overall Status

Completed (1)

Recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

National Human Genome Research Institute (NHGRI) (2)

ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) (1)

Collaborator

Worldwide Clinical Trials (1)

Intervention

mk-7075 (miransertib) (2)

miransertib (1)

Study Documents

Intervention Type

drug (3)

Funder Type

NIH (2)

Industry (1)

Study Type

Interventional (3)

Miransertib

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Proteus Syndrome Trial run by the NHGRI (MK-7075 (miransertib))

Recruiting

Proteus Syndrome

MK-7075 (miransertib)

Bethesda, Maryland

National Institutes of Health Clinical Center

Nov 19, 2022

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome Trial in Worldwide (Miransertib)

Terminated

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

Miransertib

Atlanta, Georgia
+10 more

May 10, 2022

Proteus Syndrome Trial run by the NHGRI (MK-7075 (miransertib))

Completed

Proteus Syndrome

MK-7075 (miransertib)

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Jun 29, 2022